Hypertonic saline alleviates experimentally induced cerebral oedema through suppression of vascular endothelial growth factor and its receptor VEGFR2 expression in astrocytes by unknown
Huang et al. BMC Neurosci  (2016) 17:64 
DOI 10.1186/s12868-016-0299-y
RESEARCH ARTICLE
Hypertonic saline alleviates 
experimentally induced cerebral oedema 
through suppression of vascular endothelial 
growth factor and its receptor VEGFR2 
expression in astrocytes
Linqiang Huang1†, Wei Cao2†, Yiyu Deng1, Gaofeng Zhu1, Yongli Han1 and Hongke Zeng1*
Abstract 
Background: Cerebral oedema is closely related to the permeability of blood–brain barrier, vascular endothelial 
growth factor (VEGF) and its receptor vascular endothelial growth factor receptor 2 (VEGFR2) all of which are impor-
tant blood–brain barrier (BBB) permeability regulatory factors. Zonula occludens 1 (ZO-1) and claudin-5 are also the 
key components of BBB. Hypertonic saline is widely used to alleviate cerebral oedema. This study aimed to explore 
the possible mechanisms underlying hypertonic saline that ameliorates cerebral oedema effectively.
Methods: Middle cerebral artery occlusion (MCAO) model in Sprague-Dawley (SD) rats and of oxygen–glucose dep-
rivation model in primary astrocytes were used in this study. The brain water content (BWC) was used to assess the 
effect of 10 % HS on cerebral oedema. The assessment of Evans blue (EB) extravasation was performed to evaluate the 
protective effect of 10 % HS on blood–brain barrier. The quantification of VEGF, VEGFR2, ZO-1 and claudin-5 was used 
to illustrate the mechanism of 10 % HS ameliorating cerebral oedema.
Results: BWC was analysed by wet-to-dry ratios in the ischemic hemisphere of SD rats; it was significantly decreased 
after 10 % HS treatment (P < 0.05). We also investigated the blood–brain barrier protective effect by 10 % HS which 
reduced EB extravasation effectively in the peri-ischemic brain tissue. In parallel to the above notably at 24 h follow-
ing MCAO, mRNA and protein expression of VEGF and VEGFR2 in the peri-ischemic brain tissue was down-regulated 
after 10 % HS treatment (P < 0.05). Along with this, in vitro studies showed increased VEGF and VEGFR2 mRNA and 
protein expression in primary astrocytes under hypoxic condition (P < 0.05), but it was suppressed after HS treatment 
(P < 0.05). In addition, HS inhibited the down-regulation of ZO-1, claudin-5 effectively.
Conclusions: The results suggest that 10 % HS could alleviate cerebral oedema possibly through reducing the 
ischemia induced BBB permeability as a consequence of inhibiting VEGF–VEGFR2-mediated down-regulation of ZO-1, 
claudin-5.
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Background
Cerebral oedema is an acute complication of various 
brain diseases such as cerebral ischemic stroke [1], and 
traumatic brain injury [2]. The development of cerebral 
oedema remains the most significant predictor of treat-
ment outcome. If it is not treated timely and with an 
effective strategy, it could be life-threatening due to for-
mation of cerebral hernia. To this end, osmotherapy is 
one of commonly used adjuvant therapies in clinical 
patients with cerebral oedema such as osmotic dehydrat-
ing agents including mannitol and hypertonic saline (HS) 
that are widely used to relieve cerebral oedema [3]. It is 
also well known that HS solutions may be more effective 
in ameliorating cerebral oedema than mannitol which 
is another classic osmotic dehydrating agent [3, 4]. The 
group of Schwab has been reported that 10  % HS not 
only effective in reducing the common cerebral oedema, 
but also for cases that failed with mannitol treatment [5].
The traditional theory that HS removes free water from 
the intracellular into the extracellular space through 
establishing osmotic pressure gradient and lowers 
peripheral vascular resistance has been accepted widely 
[6]. However, the action of HS beyond its osmotic effects 
has remained elusive. We have reported previously that 
HS could alleviate cerebral oedema through down-regu-
lating the expression of aquaporin-4 in astrocytes in peri-
ischemic hemispheric tissue [7, 8]. Moreover, it may be 
neuroprotective by reducing neuronal apoptosis [7] thus 
raising the possibility that HS alleviates cerebral oedema 
not only through an osmotic mechanism, but it may also 
mediate a non-osmotic molecular mechanism.
Cerebral oedema can be classified into three parts [9, 
10], it starts from a cytotoxic brain oedema to ionic brain 
oedema, and then vasogenic brain oedema which is most 
severe with a widest range of injury. The degree of cer-
ebral oedema is closely related to the change of BBB per-
meability. The BBB is composed of endothelial cells that 
line capillaries in brain parenchyma. Astrocytes, peri-
cytes and perivascular microglia around capillaries are 
very important for maintaining the proper functioning 
of BBB [11, 12]. The up-regulation of the ionic channel 
and water transporter in these cells is pivotal to hyper-
permeability in BBB [10, 13]. The above-mentioned had 
prompted us to hypothesize that water and/or ionic 
channel in cerebral cells is related to BBB permeability 
that may be the therapeutic targets of HS for ameliorat-
ing cerebral oedema.
VEGF is the major vascular permeability regulator on 
microvascular permeability. It has been reported that 
BBB permeability was significantly increased and the 
degree of cerebral oedema deteriorated abruptly after 
treatment with VEGF [14–16]. VEGFR2, a receptor of 
VEGF, plays an important role in regulating the VEGF 
function and increases vascular permeability as well [17, 
18]. Many studies have reported that VEGF and VEGFR2 
expression was significantly and time-dependently 
increased with increasing BBB permeability in acute 
phase of cerebral oedema caused by middle cerebral 
artery occlusion (MCAO) [16, 19, 20]. It has remained 
to be resolved whether VEGF and VEGFR2 expression 
would play a role in the therapeutic efficacy of HS in cer-
ebral oedema.
Because HS can alleviate cerebral oedema by down-
regulating aquaporin-4 as reported previously by us [6, 
7], it was reasoned that it would also protect BBB perme-
ability in the acute phase of cerebral oedema. The issue 
that follows is whether HS would regulate BBB permea-
bility via regulating the expression of VEGF and VEGFR2 
in astrocytes which are closely associated with the cer-
ebral vessels.
In addition, the tight junction (TJ) between endothe-
lial cells is the key element of BBB permeability, and dis-
ruption of tight junction leads to BBB breakdown [21]. 
Zonula occludens 1 (ZO-1), and claudin-5 are important 
components of tight junction, and the down-regulation 
of them would increase the permeability of BBB sig-
nificantly [22]. It remains to be ascertained whether HS 
could regulate the expression of aforementioned tight 
junction proteins.
To ascertain these possibilities, the brain water content 
(BWC), Evan’s Blue (EB) extravasation, and the expres-
sion of VEGF, VEGFR2, ZO-1, claudin-5 mRNA and 
protein in peri-ischemic brain tissue were assessed in 
an MCAO model in rats. Furthermore, VEGF, VEGFR2 
mRNA and protein expression in primary astrocytes was 
also examined. This aimed to determine if a functional 
correlation may be drawn among the various compo-
nents both in vivo and in vitro.
Methods
Animals and experimental groups
207 SPF male Sprague-Dawley (SD) rats weighing 200–
250  g (provided by Guangdong Medical Laboratory 
Animal Centre, Guangdong Province), are randomly 
divided into a sham-operated group (n  =  69), cerebral 
ischemia + normal saline group (ischemia group, n = 69) 
and cerebral ischemic + 10 % HS treatment group (10 % 
HS group, n = 69). In ischemia group and 10 % HS group, 
rats were subjected to right-sided middle cerebral artery 
occlusion (MCAO). Reperfusion started at 2  h after 
MCAO; meanwhile, the rats in the ischemia group and 
10  % HS group were treated with a continuous intrave-
nous (i.v.) infusion of normal saline (0.3 ml/h) and 10 % 
HS, respectively. However, rats in sham-operated group 
were subjected to the same operating procedure but not 
subjected to MCAO. After this, the rats were treated with 
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an i.v. infusion of normal saline (0.3 ml/h) via the tail vein 
until the end of the experiment. The rats in each group 
were further subdivided into three groups at various time 
points: 6, 12 and 24 h subgroups. Number of rats killed 
at various time points in different groups is shown in 
Table  1. All the animal experimental procedures were 
approved by Institutional Animal Care and Use Com-
mittee, Guangdong Province, China. All experiments 
were carried out in accordance with the National Insti-
tute of Health Guide for the Care and Use of Laboratory 
Animals.
Focal brain ischemia animal model
The rats were allowed free access to water but were not 
fed the night before prior to surgery. Anaesthesia was 
achieved with an intraperitoneal injection of 5  % Keta-
mine (40  mg/kg) before surgery. During the whole sur-
gical procedure, a heating lamp was used to ensure that 
the rectal temperature was maintained between 37 and 
37.5  °C. Focal cerebral ischemia was induced by intra-
luminal occlusion of the right middle cerebral artery 
as previously described [23, 24]. Briefly, after the expo-
sure of the right common carotid artery (CCA), internal 
carotid artery (ICA), and external carotid artery (ECA) 
through a midline incision along the neck, a 4–0 head 
end spherical nylon suture was inserted into the right 
ICA to block the origin of right middle cerebral artery so 
that the blood flow to the cerebral somatosensory cor-
tex was impeded. Sham-operated rats were subjected 
to the same surgical procedures without MCAO. At 2 h 
after MCAO, reperfusion was commenced by withdraw-
ing the intraluminal filament which was followed by the 
neurologic assessments. The Longa scores test was used 
to evaluate neurologic deficits after MCAO [23]: 0, no 
observable neurologic deficit; (1) a mild focal neurologic 
deficit (failure to extend left forepaw fully); (2) a moder-
ate focal neurologic deficit (circling to the left); and (3) a 
severe focal deficit (falling to the left); (4) no spontaneous 
motor activity (the rats did not walk spontaneously com-
bined with depressed levels of consciousness). The rats 
with a score of 1–3 were used in experiments.
After decapitation, peri-ischemic brain tissues were 
obtained from the superior one-third of the cortical 
area, extending from longitudinal cerebral fissure to lat-
eral cerebral fissure in the section, which was located at 
7–11 mm posterior to the tip of olfactory bulb [25].
Primary astrocyte cell culture and treatment
Rat primary astrocytes were isolated from the cerebrum 
of 0–24  h-old SD rats by a modification of a previously 
described method [26]. Briefly, rats were killed and their 
cerebral hemispheres were harvested. After the meninges 
and blood vessels were carefully cleared, the cortical tis-
sues were collected into a beaker and dissected into tis-
sue pieces of 1 mm3 size. This was followed by digesting 
in 0.125 % trypsin for 10 min at 37 °C. At the termination 
of digestion, the tissue pieces were manually dissociated 
by triturating with Dulbecco’s modified Eagle’s medium-
F12 nutrient mixture (DMEM-F12) with 10  % fetal 
bovine serum. The cell suspension was then filtrated with 
a 70  μm cell strainer and centrifuged at 1500  rpm for 
5  min. Finally, the supernatant was carefully discarded 
and the cells resuspended with 10  ml of DMEM-F12 
supplemented with 10  % FBS. The cells were plated in 
75 cm2 culture flasks at density of 2 ×  106  cells/ml and 
cultured at 37  °C in an incubator with 95 % air and 5 % 
CO2. When the culture reached its confluence, astro-
cytes were purified by shaking to remove most microglia 
and oligodendrocytes on an orbital shaker. The purified 
astrocytes were divided into three groups: control group, 
hypoxia +  glucose free medium group (Hypoxia group) 
and hypoxia + glucose free medium +100 mM HS group 
(HS group). Hypoxia group and HS group were incubated 
at 37 °C incubator filled with 3 % oxygen and 5 % CO2 for 
4 h, and the control group was cultured with DMEM-F12 
containing 10 % FBS at 37 °C in humidified 5 % CO2 and 
95 % air.
Assessment of ischemic hemispheric brain water content
Brain oedema was estimated by comparing wet to-dry 
weight ratios [27]. Briefly, at the end of the experiment, 
rats were killed by decapitation under deep anesthesia. 
The brain was quickly removed and its moisture blotted 
gently. The brain was bisected through the inter-hem-
ispheric fissure into right and left hemispheres. Subse-
quently, brain hemisphere was weighed on an electronic 
balance with a scale reading to within 0.001  mg. Dry 
Table 1 Number of rats killed at various time points in dif-
ferent groups





 6 h 6 6 9 0
 12 h 6 6 9 0
 24 h 6 6 9 6
Ischemia group
 6 h 6 6 9 0
 12 h 6 6 9 0
 24 h 6 6 9 6
10 % HS group
 6 h 6 6 9 0
 12 h 6 6 9 0
 24 h 6 6 9 6
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weight of ischemic hemispheres was measured after the 
tissue was heated for 3 days at 100  °C in a drying oven. 
Tissue water content was then calculated as follows: % 
H2O = (wet weight − dry weight)/wet weight × 100 %.
Evaluation of blood-brain barrier integrity
The integrity of the BBB was achieved by measuring 
Evans-Blue extravasated in ischemic hemispheric tissue 
as previously described [28, 29]. Evans Blue (EB, 2 % in 
saline, 4 ml/kg) was injected intravenously at the begin-
ning of reperfusion. At 24 h after MCAO, the rats were 
transcardially perfused with 110 ml saline to remove the 
intravascular Evans blue dye under deep anesthesia. The 
brain was cut into 2  mm thick coronal sections at the 
level of the optic chiasma. The ischemic hemisphere was 
then weighed and homogenized in 2 ml 50 % trichloro-
acetic acid, followed by centrifugation at 10,000 rpm for 
20 min. The supernatants were analysed at 620 nm using 
a spectrophotometer. The total Evans blue content in 
ischemic hemisphere was quantified in reference to a lin-
ear standard curve derived from known amounts of the 
dye and was expressed as micrograms per gram of tissue.
RT real-time PCR
Total RNA was extracted from peri-ischemic brain tis-
sue and primary astrocytes using the Trizol reagent 
according to the manufacturer’s protocol (Invitrogen 
Life Technologies Corporation, USA, Cat. No. 115596-
026). Total RNA concentration was quantified with a 
spectrophotometer at 260  nm. Forward and reverse 
primer sequences for the respective genes are as follows: 
VEGF (93  bp), Forward: GCTTTACTGCTGTACCTC 
CAC, Reverse: AGAAGTTCGGCAGGACAC; VEGFR2 
(180  bp), Forward: CAGACAGACAGTGGGATG GT, 
Reverse: GGTATCTGTGTCGTCTGAGTGA; β-actin (203  
bp), Forward: GCCAACACAGTGCTGTCTG, Reverse: 
TACTCCTGCTTGCTGATCCA; ZO-1 (107  bp), For-
ward: GGAGCTACGCTTGCCACACT, Reverse: GGT 
CAATCAGGACAGAAACACA GT; Claudin-5 (302 bp), 
forward: TAAGGCACGGGTAGCACTCA, Reverse: GCC 
CAGCT CGTACTTCTGTG. The expression of tar-
get genes was measured in triplicate and normalized to 
β-actin, as an internal control.
Reverse transcription was carried out as follows: 500 ng 
RNA from the respective samples combined with 2  μl 
5×  PrimeScript® Buffer (PrimeScript® RT Master Mix, 
TaKaRa Biotechnology, Dalian, Co., Ltd, China; Cat No. 
DRR036S), RNase Free dH2O was added to 10 μl. After 
heated at 37 °C for 15 min and 85 °C for 5 s, the mixture 
was stored at −20 °C. For RT-PCR, the reaction mixture 
with a 10 μl final volume was composed of 5 μl 2 × SYBR 
Green I master mix, 1 μl cDNA, 0.5 μl of 10 μM forward 
primer, 0.5  μl of 10  μM reverse primer and 3  μl RNase 
Free dH2O. After the reaction mixture was pre-incubated 
at 95 °C for 30 s. The polymerase chain reactions (PCR) 
were performed according to the following procedures 
for 35 cycles: step 1: denaturation: 95  °C, 5  s; step 2: 
annealing: 60  °C, 30 s; step 3: elongation: 72  °C, 15 s. A 
modification of 2−ct method was used to quantify the 
target gene expression [30].
Western blot
Total protein was extracted from the peri-ischemic brain 
tissue and astrocyte culture using a protein extraction 
kit (KGP701, KeyGEN biotech, Nan Jing, China). Protein 
concentration of samples was quantified using BCA-100 
protein quantitative analysing kit (KGP207, KeyGEN bio-
tech, Nan Jing, China). Protein samples were separated by 
sodium dodecyl sulfate–polyacrylamide gels and trans-
ferred to polyvinylidene difluoride transfer membranes. 
The membranes were washed with TBS—0.1  % Tween 
buffer and blocked with 5 % non-fat dry milk for 1 h at 
room temperature, and incubated with primary antibody 
as follows: VEGF (1:1000, rabbit polyclonal IgG, Santa 
Cruz, USA, Cat. No. sc-152), VEGFR2 (1:1000; rabbit 
polyclonal IgG, Santa Cruz, USA, Cat. No. sc-505), ZO-1 
(1:200; Rabbit polyclonal IgG; Invitrogen Life Technolo-
gies Corporation; Cat. No. 40-2200), Claudin-5 (1:500; 
Mouse monoclonal IgG; Invitrogen Life Technologies 
Corporation; Cat. No. 35-2500) and GAPDH (1:1000, 
Santa Cruz Biotechnology, USA, Cat. No. sc-20357) over-
night at 4  °C. After washing in TBS-0.1  % Tween three 
times, they were incubated with the horseradish per-
oxidase (HRP)-conjugated secondary antibody (1:3500, 
goat anti-rabbit, Cell Signaling Technology, USA; Cat. 
No. 7074) for 1 h. The immunoblots were developed on 
Kodak films with an enhanced chemiluminescence detec-
tion system (Bei Jing Pu Li Lai Gene Technology Co., Ltd, 
China) according to the manufacturer’s instructions. The 
band intensity of VEGF and VEGFR2 expression levels 
relative to the GAPDH was quantified by FluorChem 
8900 software (version 4.0.1, Alpha Innotech Corpora-
tion, USA).
Double immunofluorescence
At 24  h after MCAO, coronal frozen sections of the 
brain of 30 μm thickness at the level of the optic chiasma 
were cut and rinsed in PBS. Sections were incubated in 
a humidified chamber with a mixture of glial fibrillary 
acidic protein (GFAP) (1:50, monoclonal antibody IgG, 
Millipore, USA, Cat. No. MAB 360) and VEGF (1:50, rab-
bit polyclonal IgG, Santa Cruz, USA, Cat. No. sc-152) or 
VEGFR2 (1:50; rabbit polyclonal IgG, Santa Cruz, USA, 
Cat. NO. sc-505) overnight at 4  °C. Subsequently, these 
sections were washed and incubated with Alexa Fluor® 
488 goat anti-rabbit IgG (H + L) (1:200; Invitrogen Life 
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Technologies Corporation, USA; Cat. No. CA11008s) 
and Alexa Fluor® 594 goat anti-mouse IgG (1:200; Inv-
itrogen Life Technologies Corporation, USA; Cat. No. 
CA11005s) for 1  h at room temperature. After several 
washes with PBS, the sections were mounted with a fluo-
rescent mounting medium. Colocalization was observed 
by confocal microscopy (Leica TCS SP2 AOBS; Leica 
Microsystems Ltd, Germany).
At 4  h after hypoxia, astrocytes in culture were fixed 
with 4  % paraformaldehyde for 20  min. Following rins-
ing with PBS, cells were blocked with 5  % goat serum 
for 30  min, and then incubated with a mixture of anti-
bodies against GFAP (1:50; Millipore, USA, Cat. No. 
MAB 360) and VEGF (1:50; Santa Cruz, USA, Cat. No. 
sc-152) or VEGFR2 (1:50; Santa Cruz, USA, Cat. No. 
sc-505) at 4  °C overnight. On the following day, cells 
were incubated with Alexa Fluor® 488 goat anti-rabbit 
IgG (H + L) (1:200; Invitrogen Life Technologies Corpo-
ration, USA; Cat. No. CA11008s) and Alexa Fluor® 594 
goat anti-mouse IgG (1:200; Invitrogen Life Technologies 
Corporation, USA; Cat. No. CA11005s) for 1 h at room 
temperature. After rinsing with PBS and mounted with a 
fluorescent mounting medium, the cells were examined 
under a fluorescence microscope (Olympus DP73 Micro-
scope, Olympus, Tokyo, Japan).
Statistical analysis
SPSS13.0 statistical software was used to analyze data. 
Different statistical methods were applied according to 
types of data. Values were expressed as mean ±  stand-
ard deviation (±SD). Univariate-factor measurement 
data was analyzed by one-way ANOVA, but two-factor 
measurement data was analysed by two-way ANOVA. 
Multiple comparisons were analyzed by Fisher’s Least 
Significant Difference test method if the data was homo-
geneity of variance; otherwise, they were analyzed by 
Dunnett’s T3 method. The difference was considered sta-
tistically significance when P < 0.05.
Results
Ipsilateral ischemic hemispheric BWC
The Longa scores showed that no significant difference 
between ischemia group and 10 % HS group (Fig. 1A; ns: 
P  >  0.05). At 6, 12 and 24  h following MCAO, BWC in 
the ipsilateral ischemic hemispheres of ischemia group 
and 10  % HS group increased significantly when com-
pared with that in the corresponding sham operated 
groups (Fig. 1B; #P < 0.05); but, the difference in the BWC 
between ischemia group and 10 % HS group at 6, 12 and 
24 h following MCAO was significant (Fig. 1B; *P < 0.05). 
It is evident that BWC in ischemia group is significantly 
greater than that in 10 % HS group.
Determination of BBB permeability with the use of Evans 
blue
The extravasation of EB was significantly increased in 
ischemia group and 10 % HS group at 6, 12 and 24 h as 
compared with the corresponding sham groups (Fig. 1C; 
#P < 0.05). However, after 10 % HS treatment, the concen-
tration of EB in 10 % HS group was markedly decreased 
as compared with ischemia group (Fig.  1C; *P  <  0.05). 
At 24  h after MCAO, EB staining area was significantly 
increased in brain sections of ischemia group, but was 
noticeably reduced with 10 % HS treatment (Fig. 1D–F).
VEGF mRNA and protein expression in the peri-ischemic 
brain tissue
Western blot showed a moderate expression of VEGF in 
the sham group. The expression level in the peri-ischemic 
brain tissue, however, was progressively increased up 
to 24 h; thus, at 6, 12 and 24 h after MCAO, compared 
with the corresponding sham groups, VEGF protein 
expression in hypoxia group was significantly increased 
(Fig. 2A, B; #P < 0.05). Remarkably, treatment with 10 % 
HS group markedly suppressed the VEGF protein expres-
sion when compared with the corresponding ischemia 
group (Fig. 2A, B; *P < 0.05).
RT-PCR showed that in ischemia group, VEGF mRNA 
expression in the peri-ischemic brain tissue was gradu-
ally increased at 6 and 12 h, followed by a decline at 24 h. 
At each time point after MCAO, VEGF mRNA expres-
sion was significantly up-regulated as compared with the 
corresponding sham group (Fig. 2C; #P < 0.05). As com-
pared with the ischemia group, however, VEGF mRNA 
expression in 10 % HS group was significantly decreased 
(Fig. 2C; *P < 0.05).
In both sham and MCAO groups, VEGF expression was 
detected specifically in astrocytes, as confirmed by dou-
ble immunofluorescence showing colocalization of GFAP. 
At 24  h after MCAO, VEGF immunoreactivity in the 
ischemia group (Fig. 2G–I) was markedly enhanced when 
compared with the sham group (Fig.  2D–F). In 10 % HS 
group (Fig. 2J–l), VEGF expression was evidently reversed 
as compared with the ischemia group. VEGF expression as 
detected either by western or immunofluorescence in 10 % 
HS group showed that despite its reduction, it remained 
above the basal levels as expressed by the sham group. 
Furthermore, a feature worthy of note is that astrocytes in 
hypoxia group appeared hypertrophic (Fig.  2G–I) when 
compared with that in 10 % HS group and sham group.
VEGFR2 mRNA and protein expression in the peri-ischemic 
brain tissue
In ischemia group, an up-regulated VEGFR2 protein 
expression was observed in the peri-ischemic brain tissue 
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Fig. 1 Assessment of BWC and Evans blue. Bar graph A the neurological score is not significantly different between ischemia group and 10 % HS 
group at 2 h after MCAO based on Zea-longa scores (ns: P > 0.05). Bar graph B the percentage of BWC in 10 % HS group was significantly decreased 
as compared with corresponding ischemia groups at 6, 12 and 24 h after MCAO (*P < 0.05). Bar graph C 10 % HS could reduce Evans blue extravasa-
tion effectively when compared with corresponding ischemia groups at 6, 12 and 24 h after MCAO (*P < 0.05). #indicates compared with sham 
group, P < 0.05. D, E and F Evans blue extravasation in each group at 24 h after MCAO. The values are presented as the mean ± SD
(See figure on next page.) 
Fig. 2 VEGF mRNA and protein expression in the peri-ischemic brain tissue in each group. A VEGF (45 kDa) and GAPDH (37 kDa) immunoreactive 
bands, respectively. Bar graph B depicts significant changes in the optical density of VEGF expression when compared with the corresponding 
ischemia groups (*P < 0.05). Bar graph C the fold change in VEGF mRNA expression. When compared with ischemia group at 6, 12 and 24 h after 
MCAO, VEGF mRNA expression in corresponding 10 % HS group is evidently reduced (*P < 0.05). #indicates compared with sham group, P < 0.05. 
The values are presented as the mean ± SD. Confocal images showing the distribution of GFAP labeled astrocytes (D, G, J, red), VEGF (E, H, K, green), 
and GFAP labeling overlapping VEGF immunofluorescence can be seen in F, I and L. Note that VEGF expression in astrocytes (arrows) is markedly 
enhanced at 24 h following MCAO. However, after treatment with 10 % HS, it is noticeably reduced. Scale bars (D–L), 50 μm
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at 6, 12 and 24 h after MCAO when compared with the 
corresponding sham group (Fig. 3A, B; #P < 0.05). After 
treatment with 10 % HS, however, VEGF protein expres-
sion in 10 % HS group was markedly decreased in com-
parison to the ischemia group (Fig. 3A, B; *P < 0.05).
A similar pattern change was observed in VEGFR2 
mRNA whose expression was markedly increased in 
ischemia group at 6, 12 and 24 h following MCAO when 
compared with the corresponding sham group (Fig. 3C; 
#P < 0.05). Treatment with 10 % HS markedly suppressed 
the VEGFR2 mRNA expression level as compared with 
the corresponding ischemia group (Fig. 3C; *P < 0.05).
Double immunofluorescence labeling showed that 
VEGFR2 expression was specifically detected in cells, 
confirmed to be the astrocytes by double labeling with 
GFAP (Figs.  3D–L). At 24  h after MCAO, very intense 
VEGFR2 immunoreactivity was detected in ischemia 
group (Figs. 3G–I). It was also found in 10 % HS group 
(Figs.  3J–L) but the immunoreactivity was significantly 
decreased as compared with ischemia group.
VEGF mRNA and protein expression in primary astrocytes
VEGF mRNA was significantly increased in primary 
astrocytes at 4  h after hypoxia in comparison with the 
control group (Fig.  4A; #P  <  0.05), but after treatment 
with 100  mM HS, VEGF mRNA in primary astrocytes 
in HS group was significantly decreased when compared 
with that in hypoxia group (Fig. 4A; *P < 0.05). The immu-
noreactive band of VEGF protein levels that appeared at 
approximately 45 kDa, increased significantly in primary 
astrocytes at 4 h after hypoxia when compared with that 
in control group (Fig. 4B, C; #P < 0.05). However, the opti-
cal density of VEGF protein in HS group that was treated 
with 100 mM HS was significantly decreased (Fig. 4B, C; 
*P < 0.05).
The results of double immunofluorescence showed 
that VEGF expression in astrocytes was completely co-
localized with GFAP labeling. Very weak VEGF immu-
noreactivity was detected in control group (Fig.  4D–F). 
At 4  h after hypoxic exposure, VEGF immunoreactiv-
ity was markedly enhanced in astrocytes (Fig.  4G–L) as 
compared with the control group (Fig. 4D–F), but VEGF 
immunoexpression was evidently decreased at 4  h after 
treatment with 100 mM HS (Fig. 4J–L) and was compara-
ble to that in the hypoxia group (Fig. 4G–I).
VEGFR2 mRNA and protein expression in primary 
astrocytes
At 4  h after hypoxia, VEGFR2 mRNA was significantly 
increased in primary astrocytes when compared with the 
control group (Fig. 5A; #P < 0.05), but following treatment 
with 100 mM HS, VEGFR2 mRNA in primary astrocytes 
in HS group was significantly decreased in comparison 
with that in hypoxia group (Fig.  5A; *P  <  0.05). West-
ern blot analysis showed that VEGFR2 protein levels 
were significantly increased in primary astrocytes under 
hypoxic condition for 4  h when compared with that in 
control group (Fig. 5B, c; #P < 0.05). But it was decreased 
significantly in HS group that was treated with 100 mM 
HS (Fig. 5B, C; *P < 0.05).
Double immunofluorescence labeling showed that the 
GFAP labeling in astrocytes was totally coincident with 
VEGFR2 expression (Fig.  5D–L). Following hypoxic 
exposure for 4 h, VEGFR2 immunofluorescence in astro-
cytes was markedly increased in hypoxia group (Fig. 5G–
I). However, it was noticeably attenuated in 10  % HS 
group (Fig. 5J–L) when compared with hypoxia group.
Zo-1, claudin-5 mRNA and protein expression in the 
peri-ischemic brain tissue
Zo-1 and claudin-5 mRNA expression level was sig-
nificantly decreased at 6, 12 and 24  h following MCAO 
(Fig.  6A, B; #P  <  0.05); however, at 6, 12 and 24  h after 
10  % HS treatment, Zo-1 and claudin-5 were increased 
significantly when compared with the corresponding 
ischemia group (Fig. 6A, B; *P < 0.05).
At 6, 12 and 24 h after MCAO, Zo-1 and claudin-5 pro-
teins were significantly decreased (Fig. 6C, E; #P < 0.05), 
but 10  % HS inhibited the down-regulation of them at 
each time point (Fig. 6C, E; *P < 0.05, **P < 0.01).
Discussion
This study has shown that HS could significantly decrease 
cerebral oedema. The present results suggest that such an 
effect may be through restoring the BBB integrity as evi-
denced by the reduced permeability to exogenous tracer 
EB that inundated the ischemic tissue after MCAO. Con-
comitant to this is reduced VEGF, VEGFR2 and tight 
junction proteins such as ZO-1 and claudin-5 expression 
suggesting their involvement in this process. It is there-
fore suggested that 10 % HS is BBB protective in ischemic 
injuries.
Like most osmotic agents, HS could improve arterial 
pressure, lower ICP, and increase cerebral blood flow and 
oxygen delivery. It has been widely used for the treatment 
of cerebral oedema because of its efficacy of decreasing 
BWC [3]. In the present ischemia–reperfusion injury 
experimental model, an obvious cerebral oedema was 
observed; but, after treatment with 10 % HS, the BWC of 
10 % HS group was significantly decreased as compared 
with the corresponding ischemia group. These results are 
consistent with the previous studies that HS could drasti-
cally reduce BWC [31–33] and, hence, cerebral oedema.
It has been reported that the alteration of BBB per-
meability and the damage of BBB integrity were closely 
related to cerebral oedema [34]. BBB is a selective 
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Fig. 3 VEGFR2 mRNA and protein expression in the peri-ischemic brain tissue in each group. A VEGFR2 (154 kDa) and GAPDH (37 kDa) immuno-
reactive bands, respectively. Bar graph B the optical density of VEGFR2 expression in 10 % HS group at 6, 12 and 24 h after MCAO is significantly 
decreased when compared with the corresponding ischemia group (*P < 0.05). Bar graph C the fold change in VEGFR2 mRNA expression. Significant 
differences in mRNA level in ischemia group at 6, 12 and 24 h after MCAO is evident when compared with the corresponding 10 % HS groups 
(*P < 0.05). #indicates compared with sham group, P < 0.05. The values are presented as the mean ± SD. Immunofluorescence images showing the 
distribution of GFAP (D, G, J, red) and VEGFR2 (E, H, K, green) in astrocytes (arrows) after MCAO for 12 h. Co-localization of GFAP and VEGFR2 can be 
seen in F, I and L. Note expression of VEGFR2 is down-regulated after treatment with 10 % HS. Scale bars (D–L), 20 μm
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Fig. 4 VEGF mRNA and protein expression in primary astrocytes. Bar graph A VEGF mRNA expression in HS group was significantly decreased in 
comparison to hypoxia group after hypoxia for 4 h. B VEGF (45 kDa) and GAPDH (37 kDa) immunoreactive bands, respectively. Bar graph C the 
optical density of VEGF expression in HS group was drastically attenuated when compared with the hypoxia group (*P < 0.05). #indicates compared 
with sham group, P < 0.05. The values are presented as the mean ± SD. Immunofluorescence images showing GFAP labelled astrocytes (D, G, J, 
red), double labelled with VEGF (E, H, K, green). Co-localized expression of GFAP and VEGF in astrocytes can be seen in F, I and L. Note that VEGF 
expression in astrocytes is markedly enhanced at 24 h following MCAO. However, after treatment with 10 % HS, it is noticeably reduced. Scale bars 
(D–L), 20 μm
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Fig. 5 VEGFR2 mRNA and protein expression in primary astrocytes. Bar graph A VEGFR2 mRNA expression in HS group was significantly decreased 
in comparison to hypoxia group after hypoxia for 4 h. B VEGFR2 (154 kDa) and GAPDH (37 kDa) immunoreactive bands, respectively. Bar graph C 
the optical density of VEGFR2 expression in HS group was drastically attenuated when compared with the hypoxia group (*P < 0.05). #indicates 
compared with sham group, P < 0.05. The values are presented as the mean ± SD. Double immunofluorescence images show that the expression 
of GFAP (D, G, J, red), VEGFR2 (E, H, K, green). The co-localized expression of GFAP and VEGFR2 can be seen in F, I and L. Note expression of VEGFR2 is 
markedly enhanced after hypoxia which is reduced by HS. Scale bars (D–L), 20 μm
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semi-permeability membrane. It separates the brain 
parenchyma from the peripheral circulation and stabi-
lizes the microenvironment of neurons, keeping it from 
deleterious effects of certain substances from blood [11, 
35]. The disruption of BBB will lead to extravasation of 
intravascular substances into the brain extracellular 
spaces. The present results have shown that EB extravasa-
tion in the ischemic hemisphere was gradually increased 
up to 24  h. This was coupled by an increase in BWC 
after ischemia–reperfusion. The results are therefore in 
accord with previous report that ischemia–reperfusion 
caused an up-regulation of BBB permeability and break-
down [28]. As expected, after treatment with 10 % HS, EB 
extravasation was significantly decreased. These results 
demonstrate that 10  % HS ameliorates cerebral oedema 
through reduction of BBB permeability and protection of 
BBB integrity. The pertinent question arose from this was 
whether HS could perform such a function.
Fig. 6 Zo-1, claudin-5 mRNA and protein expression in the peri-ischemic brain tissue in each group. Bar graphs A, B the mRNA expressions of Zo-1, 
claudin-5 were significantly decreased at 6, 12 and 24 h after MCAO, respectively, as compared with the corresponding sham group (#indicates 
compared with the corresponding sham group, P < 0.05), but they were increased significantly at corresponding ischemia group after treatment 
with 10 % HS (*P < 0.05, **P < 0.01). C Zo-1 (225 kDa), claudin-5 (22 kDa) and GAPDH (37 kDa) immunoreactive bands, respectively. As seen in Bar 
graphs D, E the optical density of Zo-1, claudin-5 was significantly attenuated after MCAO at 6, 12 and 24 h (#indicates compared with sham group, 
P < 0.05). But 10 % HS could inhibit the down-regulation of Zo-1, claudin-5 protein expression effectively at 6, 12 h after MCAO (*P < 0.05, **P < 0.01, 
ns non-significant). The values are presented as the mean ± SD
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VEGF is known as a pivotal vascular permeability fac-
tor. In some pathological situations, such as MCAO [36], 
and brain injury [37], VEGF was remarkably increased 
in the border area of the lesion. Increased VEGF has 
been reported to induce leakage of BBB [38, 39]. This 
not only leads to the formation of cerebral oedema but 
also aggravates it [38, 40, 41]. Application of a neutraliz-
ing anti-VEGF antibody can reverse the cerebral oedema 
caused by VEGF [39]. It has also been reported that rats 
treatment with VEGF protein in early phase of cerebral 
ischemic leads to increase in BBB permeability, or even 
intracerebral haemorrhage which are reduced by VEGF 
inhibitor [38].
VEGFR2, a major receptor of VEGF, is also an impor-
tant mediator of vascular permeability [42]. It is overex-
pressed in endothelial cells, astrocytes, neuronal somata 
and processes adjacent to the damage after brain injury 
[42]. Previous reports have suggested that VEGFR2, like 
VEGF, increases with increasing BBB permeability during 
the acute phase of cerebral oedema induced by various 
injuries [16, 19, 43]. Moreover, the effects of VEGF on 
BBB junction components were VEGFR2 dependent, and 
inhibition of VEGF–VEGFR2 axis is beneficial to amelio-
rate oedema [44].
The above-mentioned findings have demonstrated 
that BBB permeability and integrity are closely linked to 
VEGF and VEGFR2. As a corollary, targeting at VEGF 
and VEGFR2 may prove to be a potential therapeutic 
strategy to prevent brain oedema formation. In view of 
this, we further defined whether HS would affect the 
expression of VEGF and VEGFR2. Indeed we show here 
that expression of VEGF, VEGFR2 mRNA and protein 
was significantly up-regulated at 6 h after MCAO peak-
ing at 12  h. More strikingly, when compared with the 
ischemia group, the 10  % HS group displays a lower 
VEGF, VEGFR2 mRNA and protein expression. The 
changes correlate with the reduced BBB permeability 
after treatment with 10 % HS. This suggests that HS may 
down-regulate the BBB permeability through inhibiting 
VEGF and VEGFR2 expression. Hypoxia inducible fac-
tor-1 (HIF-1) has been implicated in the expression of 
VEGF [45, 46] and this may offer explanation for the inhi-
bition of HS on VEGF, but further studies are necessary 
to confirm this possibility.
It is known that astrocytes play a significant role in 
maintaining BBB permeability and integrity [11, 47, 48]. 
In CNS inflammatory disease, astrocyte-derived VEGF-A 
could aggravate BBB disruption. Inhibition of the VEGF 
expression in astrocytes plays a protective role in BBB 
function [47]. The present results have shown that the 
VEGF expression in astrocytes was remarkably increased 
after MCAO, and 10  % HS could down-regulate it 
effectively. This suggests that VEGF expression is 
increased in astrocytes after ischemia–reperfusion and 
HS intervention could inhibit its expression.
In vitro, hypoxia model of primary astrocytes was 
also performed to further determine the effect of HS 
on the expression of VEGF and VEGFR2 in astrocytes. 
The results are in concert with in vivo experiments. The 
levels of VEGF, VEGFR2 mRNA and protein expres-
sion were significantly augmented, but they were mark-
edly depressed after treatment with 100 mM HS. Double 
immunofluorescence labelling also supported this which 
demonstrates that HS could directly suppress the expres-
sion of VEGF and VEGFR2 in astrocytes.
Finally, it remains to be explained on why inhibition 
of HS on VEGF and VEGFR2 expression had a benefi-
cial effect on down-regulating the permeability of BBB. 
The reason for this may be that VEGF could regulate the 
expression of components of the tight junction such as 
ZO-1, claudin-5 etc.
ZO-1 and claudin-5 are the main components of tight 
junction. Previous study has showed that VEGF could 
down-regulate ZO-1, and claudin-5 expression through 
PLCγ/PKC/eNOS signaling pathway leading to the dis-
ruption of BBB. Silencing of VEGF expression in astro-
cytes by using siRNA, or inhibiting PLCγ/PKC/eNOS 
signaling pathway in endothelial cells by specific inhibi-
tor of PLCγ and eNOS could inhibit down-regulation of 
claudin-5 and hence, the permeability of BBB is reduced 
[47].
In this study, HS could also inhibit the down-regu-
lation of ZO-1, and claudin-5 significantly. Therefore, 
the mechanism whereby HS could ameliorate cerebral 
oedema may be via inhibition of VEGF-mediated down-
regulation of ZO-1, and claudin-5 to protect the integrity 
of BBB. It is suggested that the PLCγ/PKC/eNOS signal-
ing pathway maybe involved in this process, but it needs 
to be further clarified.
It has been reported that VEGF expression is also 
detected in vascular endothelial cells and neurons. The 
possibility that HS can also inhibit VEGF expression in 
these cells should therefore be considered. In addition, 
VEGF is also known as an important driver of immune 
cell infiltration [49–51]. This implicates that inhibi-
tion of VEGF may be beneficial to reduce inflammatory 
response as well. We had reported previously that HS 
could significantly decrease TNF-α and IL-1β expres-
sion levels through inhibition of JNK signaling pathway 
in microglia [52]. It is well documented that inflamma-
tory cytokines such as TNF-α and IL-1β are also pro-
duced by astrocytes via JNK signalling pathway [53], 
and that they are known to be mediators of BBB dis-
ruption [12]. Therefore, decreasing the production of 
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proinflammatory cytokines released by astrocytes by 
HS may prove to be beneficial or protective for the per-
meability integrity of BBB. In the lack of experimental 
evidence for this in this study, this remains purely specu-
lative. This study showed that the augmented VEGF and 
VEGFR2 expression after ischemia–reperfusion plays an 
important role in increasing BBB permeability that exac-
erbates cerebral oedema as manifested by the leakage 
of EB in the peri-ischemic brain tissue and the increase 
of BWC. HS therefore has additional role by protecting 
BBB permeability and can ameliorate cerebral oedema 
through inhibition of VEGF and VEGFR2-mediated 
tight junction disruption.
Conclusion
In conclusion, we have shown that ischemia–rep-
erfusion induced up-regulated VEGF and VEGR2 
expression on astrocytes leading to subsequent down-
regulation of ZO-1 and claudin-5 which contributes to 
BBB dysfunction notably its increased permeability but 
that may be effectively reduced by HS. This has fur-
thered and amplified our understanding of the mecha-
nistic and molecular roles of HS in clinical management 
of cerebral oedema.
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